Frameshift mutants of beta-amyloid precursor protein and ubiquitin-b and their use
AssigneeGemVax AS
InventorsGustav Gaudernack, Jon Amund Eriksen, Mona Moller
Life of this patent
Estimating the term…
Abstract
Frameshift Mutants &bgr;-Amyloid precursor peptides and mutant ubiquitin-B associated with Alzheimer's disease and Down syndrome eliciting T cellular immunity for use in compositions for the treatment and/or prophylaxis of Alzheimer's disease and/or Down syndrome.
Claims26
A peptide c h a r a c t e r i s e d in that it
- a) is at least 8 amino acids long and is a fragment of a mutant βAPP and/or Ubi-B protein arising from a frameshift mutation associated with Alzheimer's disease and/or Down syndrome;
- and
- b) consists of at least one amino acid of the mutant part of the mutant βAPP and/or Ubi-B protein;
- and
- c) comprises 0-10 amino acids corresponding to the carboxyl terminus of the normal part of the protein sequence preceding the amino terminus of the mutant sequence and may further extend to the carboxyl terminus of the mutant part of the protein as determined by a new stop codon generated by the relevant frameshift mutation;
- and
- d) induces, either in its full length or after processing by antigen presenting cells, T cell responses.
A peptide according to claim l characterised in that it is selected from a group of peptides having the following sequence identity numbers:
- seq id no. 1-seq id no. 10 or a fragment of any of these.
A peptide for use in treatment of Alzheimer's disease or Down's syndrome, said peptide c h a r a c t h e r i s e d in that it
- a) is at least 8 amino acids long and is a fragment of a mutant βAPP and/or Ubi-B protein arising from a frameshift mutation associated with Alzheimer's disease and/or Down syndrome;
- and
- b) consists of at least one amino acid of the mutant part of the mutant βAPP and/or Ubi-B protein;
- and
- c) comprises 0-10 amino acids corresponding to the carboxyl terminus of the normal part of the protein sequence preceding the amino terminus of the mutant sequence and may further extend to the carboxyl terminus of the mutant part of the protein as determined by a new stop codon generated by the relevant frameshift mutation;
- and
- d) induces, either in its full length or after processing by antigen presenting cells, T cell responses.
A pharmaceutical composition comprising a peptide according to any of the above claims and a pharmaceutically acceptable carrier or diluent.
Dependencies are inferred from the claim text.